Browse the corpus

Cinacalcet hydrochloride is classified as a calcimimetic medication approved by the US Food and Drug Administration (FDA) for the management of secondary hyperparathyroidism associated with end-stage kidney disease and primary hyperparathyroidism in cases where surgical intervention is not feasible. Cinacalcet is also used off-label for the treatment of calciphylaxis in patients with advanced kidney disease or undergoing dialysis. Cinacalcet's primary indication is to lower the parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism associated with end-stage kidney disease. Cinacalcet is crucial in treating chronic kidney disease (CKD) by decreasing serum PTH levels and preventing bone deterioration in patients who frequently experience elevated phosphorus and PTH levels and fluctuating calcium levels. Cinacalcet can be utilized for treating primary hyperparathyroidism in individuals who are not suitable candidates for surgery or for whom surgery poses a high risk. By lowering PTH and serum calcium levels, cinacalcet can be combined with bisphosphonates to diminish calcium resorption from bone. Cinacalcet is often used off-label as a treatment regimen for individuals with calciphylaxis—a condition that can occur in patients with end-stage kidney disease. This activity reviews the indications, mechanism of action, adverse event profile, and other relevant interactions of cinacalcet pertinent to interprofessional healthcare team members involved in treating patients with hyperparathyroidism and related conditions. This activity allows healthcare professionals to customize treatment strategies tailored to each patient's needs by making well-informed decisions, optimizing dosage regimens, and minimizing the risk of adverse reactions, thereby delivering precise and personalized care and improving patient outcomes. Objectives: Identify patients with secondary hyperparathyroidism associated with end-stage kidney disease who may benefit from cinacalcet therapy based on clinical presentation, laboratory results, and treatment history. Implement cinacalcet therapy effectively by establishing appropriate dosing regimens and considering patient-specific factors such as kidney function, concurrent medications, and potential drug interactions.

Identify patients with secondary hyperparathyroidism associated with end-stage kidney disease who may benefit from cinacalcet therapy based on clinical presentation, laboratory results, and treatment history. Implement cinacalcet therapy effectively by establishing appropriate dosing regimens and considering patient-specific factors such as kidney function, concurrent medications, and potential drug interactions. Apply evidence-based guidelines and clinical knowledge to select optimal treatment strategies incorporating cinacalcet for patients with hyperparathyroidism, ensuring individualized care plans. Collaborate with interprofessional healthcare team members to coordinate comprehensive care for patients receiving cinacalcet, optimizing treatment outcomes. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose No toxic level of cinacalcet is recognized. Dose-limiting effects include nausea and vomiting, which would limit or preclude its use.[14] Overdosage of cinacalcet can lead to hypocalcemia. In the event of an overdose, it is crucial to closely observe individuals for the signs and symptoms associated with hypocalcemia. Management of Overdose If hypocalcemia is present, the clinician should discontinue the medication, and hypocalcemia should be treated with intravenous (IV) calcium. Other electrolyte abnormalities, including magnesium and phosphorous, should also be monitored.[14]

Amidst the escalating burden of non-communicable diseases such as cardiovascular conditions and CKD, clinicians are compelled to refine their non-surgical treatment options. Cinacalcet, a calcimimetic that mitigates the increase in PTH, is increasingly taking center stage. When formulating a multi-modal approach for conditions such as calciphylaxis, CKD, and hyperparathyroidism, this medication emerges as a cornerstone in the medical toolkit. Optimal outcomes with cinacalcet therapy are achieved through the collaboration of an interprofessional healthcare team comprising clinicians, advanced practice providers, endocrinologists, nephrologists, nurses, and pharmacists. Collaboratively, they leverage comprehensive patient information to drive the most favorable patient outcomes. Nephrologists typically prescribe cinacalcet for patients experiencing secondary hyperparathyroidism while undergoing dialysis. Endocrinologists may recommend it for individuals with primary hyperparathyroidism who are not candidates for surgery or are deemed at high risk for surgical intervention. Patients should be informed about potential adverse reactions, such as nausea and vomiting, and educated on recognizing symptoms of hypocalcemia. Close monitoring of calcium levels is imperative in these cases. Additionally, the interprofessional healthcare team should engage a clinical pharmacist to optimize therapeutic outcomes and mitigate adverse events.